Asthma is affecting approximately 300 million people worldwide with 250,000 annual deaths. The marked increase in the global prevalence of asthma is likely to continue over the next two decades. Over the years, corticosteroids remain the mainstay in the treatment of asthma despite recently raised issues regarding safety and lack of responsiveness in 5-10% of asthmatic individual. Therefore, there is an urgent need in the search of more effective and safer treatment for patients with allergic asthma which is associated with increased pulmonary inflammation and airway hyperresponsiveness. A novel curcuminoid derivative, 2,6-bis-4-(hydroxyl-3-methoxybenzylidine)-cyclohexanone (BHMC) has been designed and synthesized as a non-steroidal anti-inflammatory agent in our previous study. BHMC has been proven to inhibit the synthesis of pro-inflammatory mediators in macrophages, restores endothelium dysfunction and decreases mortality in septic mice through specific disruption on p38 MAPK enzymatic activity. Recent preliminary research findings further demonstrated potential anti-inflammatory effects of BHMC in both acute and chronic models of inflammation in rodents. The present study addressed the effects of BHMC on allergic airway inflammation in an acute murine model. Mice were sensitized with ovalbumin (OVA) and treated with various doses (0.1, 1 and 10 mg/kg) of BHMC intraperitoneally. Respiratory function was measured whereas bronchoalveolar lavage fluid (BALF), blood and lung tissue were collected. Treatment with BHMC significantly attenuated airway hyperresponsiveness, number of inflammatory cells in BALF and infiltration of inflammatory cells into the airways. These observations were further strengthened by the findings that BHMC inhibited production of Th2 cytokines and goblet cells hyperplasia without reducing the level of total IgE in peripheral blood serum. Collectively, the preventive effects of BHMC on acute allergic inflammation open further avenue of research and development of a synthetic non-steroidal small molecule, BHMC, as an additional option of currently available anti-asthma therapies.